Risk of hydroxychloroquine retinopathy in the community

• Published in: Rheumatology (Oxford, England) England), 2022-08, Vol.61 (8), p.3172-3179
• Main Authors: Dabit, Jesse Y, Hocaoglu, Mehmet, Moder, Kevin G, Barkmeier, Andrew J, Smith, Wendy M, O'Byrne, Thomas J, Crowson, Cynthia S, Duarte-García, Alí
• Format: Article
• Language: English
• Subjects: Antirheumatic Agents - adverse effects; Clinical Science; Cohort Studies; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Hydroxychloroquine - adverse effects; Male; Retinal Diseases - chemically induced; Retinal Diseases - epidemiology; Tomography, Optical Coherence - methods
• ISSN: 1462-0324; 1462-0332
• DOI: 10.1093/rheumatology/keab844

We aimed to estimate the risk of HCQ retinopathy and its risk factors among incident users in the community. Using the Rochester Epidemiology Project, a record-linkage system, a cohort of incident users of HCQ was identified from 27 counties in the American upper Midwest. HCQ retinopathy was defined based on characteristic paracentral automated 10-2 visual field (10-2 AVF) defects and parafoveal retinal photoreceptor layer changes on spectral domain optical coherence tomography. Cumulative incidence rates were estimated adjusting for competing risk of death. Risk factors for HCQ retinopathy were examined using Cox models. The study included 634 incident HCQ users (mean age at initial HCQ use was 53.7 years, 79% females, 91% white). Most common indications for HCQ were RA (57%) and SLE (19%). The average follow-up length was 7.6 years. Eleven patients developed HCQ retinopathy (91% females, 91% white). The majority used HCQ for RA (91%). The cumulative incidence rate at year 5 was 0%, which increased to 3.9% (95% CI 2.0, 7.4) by 10 years. Taking an HCQ dose ≥5 mg/kg was associated with a hazard ratio (HR) of 3.59 (95% CI 1.09, 11.84) compared with lower doses. There was a 48% increase [HR 1.48 (95% CI 1.03, 2.14)] in the risk of HCQ retinopathy for each 100 g of HCQ cumulative dose. The risk of HCQ retinopathy at 10 years of use is lower compared with previous prevalence-based estimations. A dose ≥5 mg/kg was associated with higher HCQ retinopathy risk.